AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback